Reduced Coenzyme Q10 Powder Crystallinity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing reduced coenzyme Q10 powder face challenges such as high crystallinity, low bioavailability, and the need for toxic solvents for purification, limiting its extensive application.
Innovation Solution
A method involving the reduction of oxidized coenzyme Q10 in an organic solvent with a reductant like hyposulphurous acid, followed by spraying the molten reduced coenzyme Q10 liquid into cold air to produce a powder with lower crystallinity and higher bioavailability, using a centrifugal sprayer and adding antioxidants and excipients for enhanced stability and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If reduced coenzyme Q10 is obtained by crystallization in organic solvent, then the product can be obtained in solid form, but the crystallinity is high and bioavailability is low
Solution Approach 1:
The patent changes the physical and chemical parameters of the crystallization process, including using specific solvents (acetone, ethanol, isopropanol), controlling temperature ranges (40-60°C), and adjusting solvent-to-substrate ratios to obtain crystals with optimized crystallinity and bioavailability
Solution Approach 2:
The patent utilizes phase transition during crystallization by controlling the cooling rate and temperature conditions to transform the reduced coenzyme Q10 from a high-crystallinity state to a lower-crystallinity state with improved bioavailability
2Ease of manufacture
If vegetable oil is used as solvent for reduction reaction, then the reaction can proceed effectively, but toxic solvents like n-hexane are needed to remove oil from crystal surface
Solution Approach 1:
The patent employs a washing process using ethanol or isopropanol to remove vegetable oil residues from the crystal surface after reduction reaction, eliminating the need for toxic n-hexane while maintaining product purity
Solution Approach 2:
The patent replaces expensive and toxic purification solvents with cheaper, safer alcohol-based washing solutions that effectively remove oil residues without requiring complex purification steps
3Productivity
If oxidized coenzyme Q10 is reduced using conventional methods, then reduced coenzyme Q10 can be obtained, but the process requires multiple purification steps and toxic solvents
Solution Approach 1:
The patent combines the reduction reaction and crystallization steps into a more integrated process, where the reaction mixture is directly crystallized after filtration, reducing the number of separate purification steps required
Solution Approach 2:
The patent extracts and removes impurities through simple filtration of the reaction mixture and washing of crystals with alcohol, eliminating the need for complex multi-step purification procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a reduced coenzyme Q10 powder with higher purity and bioavailability, improved stability, and reduced crystallinity, suitable for various applications including pharmaceuticals, health foods, and cosmetics, with enhanced absorption characteristics.
Implementation Method 1
adding a reductant for reaction; wherein the reductant is selected from one or more of hyposulphurous acid or salt thereof, ascorbic acid or salt thereof, carbodithioic acid or salt thereof, or reductase
Implementation Method 2
spraying by a centrifugal sprayer, to form particles in cold air after spraying
Implementation Method 3
spraying by a centrifugal sprayer, to form particles in cold air after spraying; the temperature of the cold air is not higher than 30°C
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-Kα X-ray diffraction spectrum, has a strong peak at a diffraction angle 2θ being 18.9 DEG , and has a very strong absorption peak at a diffraction angle 2θ being 22.8 DEG. The reduction type coenzyme Q10 powder is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability.